Xilio Therapeutics (XLO) Non-Current Debt (2020 - 2023)

Xilio Therapeutics has disclosed Non-Current Debt across 4 years of filings, most recently posting $1.5 million for Q1 2023.

• Non-Current Debt for Q1 2023 came in at $1.5 million, down 80.68% year-over-year; the trailing twelve-month figure through Mar 2023 was $1.5 million (down 80.68% YoY), and the FY2022 annual result was $3.2 million, down 67.13% from the prior year.
• Non-Current Debt came in at $1.5 million for Q1 2023 at Xilio Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q4 2021 to a low of $1.5 million in Q1 2023.
• The 4-year median for Non-Current Debt is $6.9 million (2020), against an average of $6.3 million.
• Across the five-year window, Non-Current Debt climbed 29.9% in 2021 and slumped 80.68% in 2023, its largest moves.
• Xilio Therapeutics' Non-Current Debt stood at $7.4 million in 2020, then climbed by 29.9% to $9.6 million in 2021, then plunged by 67.13% to $3.2 million in 2022, then plunged by 51.09% to $1.5 million in 2023.
• The last three Non-Current Debt figures came in at $1.5 million (Q1 2023), $3.2 million (Q4 2022), and $4.8 million (Q3 2022), per Business Quant data.